Publications by authors named "Aaron Boster"

Claim this Profile
T
Toward Precision Phenotyping of Multiple Sclerosis.
David Pitt, Chih Hung Lo, Susan A Gauthier, Richard A Hickman, Erin Longbrake, Aaron Boster

Neurol Neuroimmunol Neuroinflamm· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
Alasdair J Coles, Joanne L Jones, Patrick Vermersch, Anthony Traboulsee, Ann D Bass, Aaron Boster

Mult Scler· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years.
Ann D Bass, Rafael Arroyo, Aaron L Boster, Alexey N Boyko, Sara Eichau

Mult Scler Relat Disord· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.
Alasdair J Coles, Douglas L Arnold, Ann D Bass, Aaron L Boster, D Alastair S Compston

Ther Adv Neurol Disord· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Giancarlo Comi, Raed Alroughani, Aaron L Boster, Ann D Bass, Regina Berkovich

Mult Scler· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.
Dana Horáková, Aaron Boster, Antonio Bertolotto, Mark S Freedman, Isabel Firmino

Mult Scler J Exp Transl Clin· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Bart Van Wijmeersch, Barry A Singer, Aaron Boster, Simon Broadley, Óscar Fernández

Mult Scler· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis.
Timothy L Vollmer, Jeffrey A Cohen, Enrique Alvarez, Kavita V Nair, Aaron Boster

Mult Scler Relat Disord· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS Survey.
Ann D Bass, Bart Van Wijmeersch, Lori Mayer, Mathias Mäurer, Aaron Boster

Int J MS Care· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracerebral haemorrhage during alemtuzumab administration.
Christina J Azevedo, Christen Kutz, Amy Dix, Aaron Boster, Nerses Sanossian

Lancet Neurol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.
Krista Barclay, Robert Carruthers, Anthony Traboulsee, Ann D Bass, Christopher LaGanke, Aaron Boster

Front Neurol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist.
Edward J Fox, Guy J Buckle, Barry Singer, Vibhuti Singh, Aaron Boster

Neurol Clin Pract· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data.
Jacqueline Nicholas, Aaron Boster, Ning Wu, Wei-Shi Yeh, Monica Fay

Pharmacoecon Open· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database.
Aaron Boster, Jacqueline Nicholas, Ning Wu, Wei-Shi Yeh, Monica Fay

Neurol Ther· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Best Practices for Intrathecal Baclofen Therapy: Dosing and Long-Term Management.
Aaron L Boster, Roy L Adair, Judith L Gooch, Mary Elizabeth S Nelson, Andrea Toomer

Neuromodulation· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Best Practices for Intrathecal Baclofen Therapy: Screening Test.
Aaron L Boster, Susan E Bennett, Gerald S Bilsky, Mark Gudesblatt, Stephen F Koelbel

Neuromodulation· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Best Practices for Intrathecal Baclofen Therapy: Patient Selection.
Michael Saulino, Cindy B Ivanhoe, John R McGuire, Barbara Ridley, Jeffrey S Shilt, Aaron L Boster

Neuromodulation· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Best Practices for Intrathecal Baclofen Therapy: Troubleshooting.
Michael Saulino, David J Anderson, Jennifer Doble, Reza Farid, Fatma Gul, Aaron L Boster

Neuromodulation· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.
Jacqueline Ann Nicholas, Aaron Lee Boster, Jaime Imitola, Colleen O'Connell, Michael Karl Racke

Drug Des Devel Ther· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of video-game training on broad cognitive transfer in multiple sclerosis: A pilot randomized controlled trial.
Alisha Janssen, Aaron Boster, HyunKyu Lee, Beth Patterson, Ruchika Shaurya Prakash

J Clin Exp Neuropsychol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.
Aaron L Boster, Corey C Ford, Orit Neudorfer, Yossi Gilgun-Sherki

Expert Rev Neurother· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration.
Joshua C Orack, Michela Deleidi, David Pitt, Kedar Mahajan, Jacqueline A Nicholas, Aaron L Boster

Stem Cells Transl Med· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Tomas Olsson, Aaron Boster, Óscar Fernández, Mark S Freedman, Carlo Pozzilli

J Neurol Neurosurg Psychiatry· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing loss of intrathecal baclofen efficacy: Review of the literature and proposed troubleshooting algorithm.
Aaron Boster, Jacqueline Nicholas, Mary Pat Bartoszek, Colleen O'Connell, Chima Oluigbo

Neurol Clin Pract· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.
Jacqueline Ann Nicholas, Michael Karl Racke, Jamie Imitola, Aaron Lee Boster

Ther Adv Chronic Dis· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis